A patient who has undergone urological surgery is prescribed urinary catheterization

The best treatment for localized prostate cancer is a radical prostatectomy. Generally, the complications of radical prostatectomy were male sexual dysfunction and urinary incontinence [3]. The degree of urinary incontinence may vary according to the preservation of periurethral tissue [4]. Patients who have undergone a radical prostatectomy should perform pelvic floor muscle exercises or pelvic floor muscle training during the immediate post-operative period. On the other hand, artificial sphincter insertion is recommended if these methods are ineffective [5]. This operative therapy cannot be applied to all patients because of various etiologies. If so, many physicians might misuse an indwelling catheter to control the incontinence. This may induce various catheter-related problems, such as urinary tract infection, urethral stricture, and urethral rupture [6]. Therefore, The Canadian Agency for Drugs and Technologies in Health does not recommend the long-term use of a urethral catheter in patients with urinary incontinence [7].

For patients who have used indwelling catheters for long periods, it is necessary to check whether there is inflammation in the scrotum, even if there is no chronic disease such as diabetes. In addition, conservative management, including broad-spectrum antibiotic treatment and blood pressure control, should be considered.

Although the cause of the Fournier’s gangrene was a perineal abscess, it may also occur when chronic catheterization is performed. Predisposing factors include diabetes mellitus, chronic renal failure, and congestive heart failure [1]. One research reported that the diagnosis time is crucial because it correlates directly to a person’s death. The death rate of the surgical intervention within two days after hospitalization was significantly lower than the procedure delayed 3 to 5 days [8].

Although most of the causative bacteria of Fournier’s gangrene are polymicrobial, Escherichia coli, Bacteroides spp., and Staphylococci, Proteus spp. are the main microorganisms. Other bacteria were identified in blood and wound cultures in this case. Nevertheless, research reported no correlation between the strain of microorganisms and mortality [9].

In conclusion, Fournier’s gangrene requires urological emergency procedures, particularly for patients with the long-term use of a urethral catheter. These patients require careful physical examinations and immediate treatment to obtain good results.

  • Journal List
  • HHS Author Manuscripts
  • PMC4965327

J Urol. Author manuscript; available in PMC 2017 Aug 1.

Published in final edited form as:

PMCID: PMC4965327

NIHMSID: NIHMS755597

Ana L. Flores-Mireles,#1,2 Jennifer N. Walker,#1,2 Tyler M. Bauman,#3 Aaron M. Potretzke,3 Henry L. Schreiber, IV,1,2 Alyssa M. Park,3 Jerome S. Pinkner,1,2 Michael G. Caparon,1,2 Scott J. Hultgren,1,2 and Alana Desai#,3

Abstract

Purpose

Catheter-associated urinary tract infections (CAUTI) account for ~40% of all hospital-acquired infections worldwide, with more than one million cases diagnosed annually. Recent data from a CAUTI animal model has shown that inflammation induced by catheterization releases host fibrinogen that accumulates on the catheter. Further, Enterococcus faecalis catheter colonization was found to be dependent on EbpA, a fibrinogen binding adhesin. We sought to evaluate this mechanism in a human model.

Materials and methods

Urinary catheters were collected from human subjects hospitalized for surgical or non-surgical urologic procedures. Catheters were subjected to immunofluorescence analyses by incubating them with anti-fibrinogen antibody and then stained for fluorescence. The fluorescence intensity was compared to standard catheters. Catheters were incubated with strains of Enterococcus faecalis, Staphylococcus aureus, or Candida to assess their binding to fibrinogen-laden catheters.

Results

Fifty catheters were collected after various surgical and urological procedures. In vivo dwell time ranged from 1 hour to 59 days. All catheters had fibrinogen deposition and its accumulation was dependent on dwell time but not on surgical procedure or catheter material. Catheters were probed ex vivo with E. faecalis, S. aureus, and Candida albicans, which bound to catheters only in those regions where fibrinogen was deposited.

Conclusions

Taken together, these data show that urinary catheters act as a binding surface for accumulation of fibrinogen, which is released due to inflammation resulting from a urological procedure or from catheter placement, creating a niche that can be exploited by uropathogens to cause CAUTI.

Keywords: Urinary catheterization, CAUTI, fibrinogen, catheter, inflammation

INTRODUCTION

Urinary tract infections (UTIs) represent a significant burden to the healthcare system, affecting approximately 150 million people worldwide1, 2, with an estimated per annum cost of $2-3 billion in the United States2. Serious sequela can result from UTIs including pyelonephritis and bacteremia, resulting in severe morbidity and mortality3. Hospitalization is a risk factor for UTI, with an estimated risk on any day of 1.1-6.5%. Catheterized patients have substantially higher risk than patients without exposure to a catheter4 and virtually all patients will develop bacteriuria within 30 days of catheter placement1, 5, 6. Urinary catheters are the second leading cause of hospital-acquired bacteremia leading to 7-day mortality rates of over 30%7. Furthermore, the emergence of multidrug resistant microorganisms such as vancomycin-resistant enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA) and fluoroquinolone resistance in Escherichia coli is of critical concern2, 8, 9. The overuse of antibiotics during UTI can lead to fungal infection and is a universal risk for acquiring Candida UTI10. Therefore, understanding the interplay between uropathogen virulence factors and the patient response will pave the way for the development of alternative treatments to reduce antibiotic use.

In a murine model of catheter-associated UTI (CAUTI)11, fibrinogen deposition on catheters is the key pathogenic event leading to colonization by Enterococcus faecalis12. In this model, circulating fibrinogen increases in response to tissue damage from catheter placement, enters the bladder and is deposited on catheters in a time-dependent manner. E. faecalis adheres to the deposited fibrinogen using a hair-like heteropolymeric surface protein, the endocarditis- and biofilm-associated pilus (Ebp)12-14. The EbpA subunit located at the tip of the fiber binds fibrinogen to facilitate catheter-associated biofilm formation12, 15 and vaccination with EbpA attenuates E. faecalis colonization and biofilm formation during catheterization12. The goal of this study was to translate these observations from the murine model to human disease by: 1) investigating the deposition of fibrinogen on human urinary catheters and; 2) using an ex-vivo assay to assess whether fibrinogen deposits can potentiate colonization by several common uropathogens, including E. faecalis, S. aureus and Candida albicans.

METHODS

Bacterial strains and growth conditions

Strains included E. faecalis OG1RF (SJH-1994), its isogenic EbpA mutant that can express Ebp, but cannot bind to fibrinogen (SJH-2001)12, S. aureus (SJH-1369) and Candida albicans (SJH-3140). Liquid cultures used Brain Heart Infusion broth (BHI) (BD Company) inoculated from a single colony grown on Brain Heart Infusion plates and were grown shaking at 200rpm (S. aureus, Candida albicans) or statically (E. faecalis) at 37°C for 18 h.

Antibodies

Primary antibodies: Goat anti-human fibrinogen (cat#F8512, Sigma-Aldrich); rabbit anti-Streptococcus group D antigen (anti-Enterococcus faecalis) (Lee Laboratories)12; rabbit anti-Protein A antigen (anti-Staphylococcus aureus) (cat#P3775; Sigma-Aldrich), rabbit anti-Candida albicans (cat#ab53891; Abcam). Secondary antibodies: IRDye 800CW donkey anti-goat (cat#926-32213); and IRDye 680LT goat anti-rabbit (cat#926-68021) from LI-COR Biosciences.

Collection of urinary catheters

Urinary catheters consisting of 100% silicone, silicone elastomer or latex were placed for surgical or non-surgical urologic procedures in consented patients (Table 1). The gender, procedure type, catheter material, dwell time, prior urine culture, and antibiotics prescribed were recorded for each patient. This study was approved by the Washington University School of Medicine Internal Review Board (approval #201410058).

Table 1

Information on urinary catheters placed as a standard of care.

Pt
#
GenderProcedureDwell
time
Fg
(mg/catheter)
Preop
Urine culture
Preop
antibiotics
Postop
antibiotic
Catheter
material
1 F Neurogenic
bladder#
21
days
17.2 N/A None None Latex

2 M RRP 9 days 9.8 Gram + None Cipro 500mg Silicone

3 M RRP 10
days
15.4 Neg None Cipro 500mg Silicone

4 M RRP 7 days 21.1 Neg None Cipro 500mg Silicone

5 F Partial
nephrectomy
26 hrs 3.6 Neg IV Cefazolin
2g
IV Cefazolin
2g
Silicone

6 F PCNL 18 hrs 22.5 E. faecalis,
MRSA
IV Cipro 2g
IV Vanco 1g
IV Cefepime
2g
Silicone

7 F PCNL 26 hrs 3.7 Neg IV Cipro
400mg
IV Vanco 1g
IV Cipro
500mg
Silicone

8 M TURBT 27.5
hrs
17.5 Neg IV Cipro
400mg
Mytomycin-C Silicone

9 F Partial
nephrectomy
2 days 0.004 Neg IV Cefazolin
3g
IV Cefazolin
2g
Silicone

10 M RRP 8 days 2.7 Neg None Cipro 500mg Silicone

11 F Stent placement
for
hydronephrosis
4 days 1.0 N/A None None Silicone

12 F PCNL 2 days 6.6 S. aureus IV Cefepime
1g
IV Vanco 1g
IV Cefepime
2g
IV Vanco 1g
Silicone

13 M PCNL 24 hrs 2.1 Neg IV Cefazolin
3g
Cipro 500mg Silicone

14 F Partial
nephrectomy
18 hrs 2.2 Neg IV Cefazolin
2g
IV Cefazolin
2g
Silicone

15 F Incontinence# 46
days
20.9 N/A None None Latex

16 M Meatal stenosis
and retention*
29
days
17.3 N/A Bactrim DS
500mg BID
None Latex

17 M RRP 9 days 0.7 Neg None Cipro 500mg Silicone

18 M SPT for
neurogenic
bladder*
59
days
33.1 N/A None None Silicone
elastomer

19 F SPT for
neurogenic
bladder*
38
days
17.2 Neg U/A U/A Latex

20 F Max drainage
for r/o sepsis
subsequent to
pyelonephritis#
22 hrs 2.8 Actino-
baculum
U/A U/A Silicone
elastomer

21 M PCNL 23 hrs 0.004 Coagulase
Negative
Staphylococci
IV Cipro
400mg
IV Vanco 1g
Cipro 500mg
BID
IV Vanco 1g
Latex

22 F PCNL 21 hrs 2.2 Neg IV Cipro
400mg
IV Cefazolin
2g
Cipro 500mg
BID
Silicone

23 F PCNL 20 hrs 0.6 Neg IV Cefazolin
2g
IV Cefazolin
2g
Silicone

24 F Urethral sling 17 hrs 1.9 Neg IV Cipro
400mg
IV
Metronidazole
500mg
Cipro 500mg
BID
Silicone
elastomer

25 M Nephrectomy 28 hrs 0.1 Neg IV Cefazolin
3g
Rifaximin
550mg BID
Silicone

26 M Radical
nephrectomy
23 hrs 0.2 Neg IV Cefazolin
2g
IV Cefazolin
2g
Silicone

27 M RRP 8 days 0.2 Neg None Cipro 500mg Silicone

28 M PCNL 25 hrs 0.1 Neg IV Cipro
400mg
IV Cefazolin
2g
IV Cipro
500mg
Silicone

29 F PCNL 24 hrs 0.42 Neg IV Cipro
400mg
IV Vanco
100mg
IV Cipro
400mg
Silicone

30 M Nephrectomy 26 hrs 0.4 Neg IV clindamycin
900mg
None Silicone

31 M RRP 8 days 0.3 Neg IV Cefazolin
1g
cephalexin
500mg
cipro 500mg
Silicone

32 M Nephrectomy 18 hrs 0.1 Neg IV Cefazolin
2g
None Silicone

33 F Nephrectomy 22 hrs 0.9 Neg IV Cefazolin
2g
cefazolin 1g Silicone

34 F Ureteroscopy 2 days 7.7 E. coli BID
BactrimDS
800mg
Doxycycine
hyclate 100mg
IV Cipro
326mg
IV cefepime 1g Latex

35 M Nephrectomy
with stent
placement
17 hrs Neg IV Cipro
400mg
IV Cefazolin
2g
IV Cefazolin
10g
Silicone

36 F Nephrectomy 28.5
hrs
Neg IV Cefazolin
2g
IV Cefazolin
1g
Silicone

37 M Male sling 19.5
hrs
3.5 N/I IV Vanco 1g IV Vanco 5 g Silicone

38 M Artificial
urinary
sphincter
23 hrs 2.5 Neg IV piperacillin/
taxoactam
3.375g/IV
vanco 1g
Ampicillin/sulb
actam 15g
Vanco 5g
Latex

39 M Radical
nephrectomy
19 hrs 7.3 Neg IV Cefazolin
3g
None Silicone

40 F Partial
nephrectomy
17 hrs 10.4 IV Cefazolin
2g
None Silicone

41 F PCNL 22.5
hrs
8.6 Neg IV Cefazolin
2g
None Silicone

42 M PCNL 16 hrs 23.1 N/A IV Cefapime
2g
IV Vanco 5g
None Silicone

43 M Percutaneous
resection of
right renal
pelvic tumor
23 hrs 2.4 Neg BID cipro
500mg
IV gentamycin
300mg
IV Cefazolin
2g
None Silicone

44 M Right
pyeloplasty
26.5 hrs 13.7 Gardnerella
vaginalis
IV Cefazolin
2g
IV
Metronidazole
500mg
IV Cefazolin
2g
Silicone

45 M Partial
nephrectomy
17 hrs 4.4 N/I IV Cefazolin
2g
IV Cefazolin
2g
Silicone

46 M Partial
nephrectomy
23
hrs
9.8 N/I IV Cefazolin
2g
IV Cefazolin
2g
Silicone

47 M Partial
nephrectomy
19.5
hrs
15.8 Neg IV Cefazolin
2g
None Silicone

48 M Partial
nephrectomy
26 hrs 2.2 Neg IV Cefazolin
2g
None Silicone

49 F Excision of
eroded mesh
1 hr 1.2 Neg 400mg
IV
Metronidazole
500mg
None Silicone
elastomer

50 F Mid urethral
sling placement
1.5 hrs 0.7 Neg IV Cefazolin
2g
IV
Metronidazole
500mg
None Silicone
elastomer

Analysis of fibrinogen deposition

After collection, catheters were cut into 10 cm segments, fixed with formalin for 1 hour and washed 3 times with PBS. For analysis, the first 10 cm of the catheter’s tip was blocked by overnight incubation at 4°C with 1.5% BSA with 0.1 % sodium azide in PBS, then washed three times for 5 min each with PBS-T (PBS containing 0.05% Tween-20). A 15 ml solution containing goat anti-human fibrinogen diluted 1:500 in PBS-T was added and incubated at room temperature for 2 hrs. Catheters were then washed 3 times for 5 min each with PBS-T, and incubated with donkey anti-goat IRDye 800CW (diluted 1:10,000) for 45 min at room temperature. Following an additional 3 washes with PBS-T, catheters were examined for infrared signal using the Odyssey Imaging System (LI-COR Biosciences). Auto-fluorescence was assessed in non-implanted catheters and catheters not incubated with the primary antibody, which was minimal.

Quantification of fibrinogen

The concentration of fibrinogen deposited on clinical catheters was determined by comparison of the infrared signal following staining to a standard curve prepared by incubation of fibrinogen (0.0001 mg/ml-10 mg/ml) with non-implanted catheters that were then processed as described above. Separate curves were generated for each type of catheter material. A linear relationship model was used to compare the amount of fibrinogen deposition to variables (dwell times/surgical procedure/bacterial positive urine cultures) that was tested for significance by Pearson’s correlation using GraphPad Prism software.

Binding to catheters ex-vivo

Catheters from patients with negative urine cultures were treated as described above, except that antibody was replaced with uropathogens as follows: Overnight cultures were washed and resuspended in PBS and cell densities normalized to an OD600 of 0.5 (~2 ×107 CFU for E. faecalis and S. aureus strains; ~2×104 for C. albicans) and 15 ml of the suspension incubated with the patient catheter at 37°C with shaking conditions (100 rpm). Uninfected control catheters were incubated with PBS alone. Following 1 hr, catheters were then washed 3 times with PBS to remove unbound microorganisms, were fixed with formalin for 20 min at room temperature, then washed 3 times with PBS and blocked with 1.5 % BSA and 0.1 % sodium azide in PBS at 4°C overnight. Catheters were then washed 3 times with PBS-T and stained with rabbit antibodies against each pathogen and with goat anti-human fibrinogen (all diluted 1:500), were washed an additional 3 times with PBS-T and incubated with secondary antibodies and scanned for infrared signal as described above. Images were analyzed using Odyssey Infrared Imaging software (version 3.0.16) to measure relative infrared fluorescence at 800 nm and 700 nm, corresponding to fibrinogen and microorganism, respectively. Auto-fluorescence, as determined from non-implanted catheters and catheters incubated only with the secondary antibody, was minimal (typically <0.05% of infected catheters).

RESULTS

Fibrinogen is deposited on human urinary catheters and deposition is dependent on dwell time

Fifty adult patients undergoing urinary catheterization as a standard of care were consented for this study in the Division of Urology at Washington University School of Medicine. Patient gender, the procedure requiring catheterization, catheter type and material, catheter dwell time, urine culture results prior to the procedure (if any), and any antibiotics prescribed are detailed in Table 1. Catheters were collected from both male and female patients undergoing a range of surgical and non-surgical urological procedures and had dwell times from as little as 1 hr to 59 days (Table 1). Silicone catheters were most commonly collected in the study (Fig. 1). We found that regardless of gender, procedure, or catheter material, all catheters stained positive for fibrinogen (Fig. 1). The concentration of fibrinogen deposited on the catheters was quantified (mg/catheter) by using a standard curve for each catheter material (Table 1). Correlation analysis showed that the concentration of fibrinogen was dependent on the dwell time (r=0.6312, p=<0.0001; Fig. 2A); however, there was not a positive correlation between concentration of fibrinogen deposition and surgical procedure (r=−0.1181, p=<0.4139) (surgical procedures are grouped by color, Fig. 2A, B). Furthermore, positive preoperative urine cultures do not have a significant correlation with fibrinogen deposition (r=0.1449, p=<0.3153) (square symbols, Fig. 2A and B). Based on these data, dwell time is the main determinant influencing the concentration of fibrinogen deposition.

A patient who has undergone urological surgery is prescribed urinary catheterization

Representative images of the different urinary catheter materials and visualization of their fibrinogen deposition

A) 100 % silicone; B) silicon elastomer; and C) latex. The first 10 cm of the catheter tip was used for fibrinogen deposition analysis. Deposited fibrinogen on the catheter was detected by immunofluorescence using goat anti-human fibrinogen antibody staining.

A patient who has undergone urological surgery is prescribed urinary catheterization

Correlation between the fibrinogen deposition on urinary catheters and their dwell time

(A) All fifty patient urinary catheters placed as a standard of care were recovered and fixed with formalin. The tip section (10 cm) of each catheter was subjected to analysis by immunofluorescence using antibody staining to detect deposited fibrinogen. (B) Close up view of the catheters with dwell time up to 50 hrs. Quantification of fibrinogen deposition was calculated by standard curves based on each catheter material. The color represents the surgical procedure that the patient underwent and squares denote those patients that had a preoperative positive urine culture. Pearson’ correlation statistical analysis was performed to measure the correlation between fibrinogen deposition and dwell time.

Deposited fibrinogen on catheter facilitates colonization by uropathogens

We then investigated whether uropathogens could attach to the fibrinogen deposited on human urinary catheters. For this experiment, we analyzed two strains: i) the E. faecalis strain (OG1RF) that expresses the fibrinogen binding EbpA protein and; ii) an isogenic mutant derived from this strain that contains a mutated EbpA protein rendering it unable to bind to fibrinogen (AWAGA)5, 16. As an additional comparison, the urinary catheters were mock infected with PBS alone. To monitor auto-fluorescence, control catheters were incubated only with secondary antibodies and no bacteria. The catheters that were used were from patients identified to have negative urine cultures prior to their procedures. Immunofluorescence staining revealed that these catheters had deposited fibrinogen (top, Fig.3A) and that E. faecalis OG1RF, but not the fibrinogen-binding mutant (AWAGA), was able to bind to catheters (middle, Fig. 3A). Furthermore, the areas of bacterial adherence co-localized with the pattern of fibrinogen deposition (bottom, Fig. 3A).

A patient who has undergone urological surgery is prescribed urinary catheterization

Ex-vivo binding of uropathogens encoding fibrinogen-binding proteins to fibrinogen deposited on human urinary catheters

Urinary catheters from patients with preoperative negative urine culture were used to test the binding of A) E. faecalis, B) S. aureus, and C) C. albicans to fibrinogen deposited onto the catheter. Catheters were incubated with 2 × 107 CFU of the corresponding strain for 1 hour. Detection of the presence and distribution of bacteria and Fg was assessed by immunofluorescent staining. A non-infected catheter was used for each strain for comparison. Catheters incubated only with the secondary antibodies were used as a negative control to assess auto-fluorescence background of the catheter material. Moreover for the E. faecalis binding experiment (A), we used the E. faecalis wild type (OG1RF) and a known fibrinogen deficient mutant (AWAGA) for comparison.

Two other prominent uropathogens were similarly tested: i) a UTI MSRA clinical isolate of the gram-positive bacterium Staphylococcus aureus and; ii) a kidney stone clinical isolate of the fungal pathogen Candida albicans. Both of these species have been reported to encode fibrinogen-binding proteins. Similar to E. faecalis, both MSRA (Fig. 2B) and C. albicans (Fig. 3C) bound to catheters in patterns that co-localized with deposited fibrinogen. These data suggest that fibrinogen deposition on the catheter creates an ideal environment for microorganisms that are able to exploit fibrinogen during attachment and colonization.

DISCUSSION

In this study, we have shown that fibrinogen is released and deposited on human urinary catheters, where it can facilitate the colonization of uropathogens. These data corroborate results from the murine model of CAUTI to provide important insight into host-pathogen interactions in the pathogenesis of CAUTI.

This study also extends prior reports that human urinary catheterization causes histological and immunological changes in the bladder due to mechanical stress, resulting in a robust inflammatory response, exfoliation, edema of the lamina propria and submucusa, urothelial thinning, and mucosal lesion of the urothelium and kidney17, 18. Based on this study, fibrinogen release into the bladder could be caused by the inflammatory response due to the surgical procedure, hematuria, or the placement of the catheter itself. Here we show the presence of a urinary catheter provides a surface for fibrinogen deposition, creating a reservoir that can be exploited by uropathogens to colonize and persist in the bladder19. Furthermore, the finding that fibrinogen deposition increases with extended time of catheterization may provide a mechanistic explanation for the lower infection levels that result from clean intermittent catheterization as compared to indwelling or re-use catheterization in patients with urinary retention20.

Similar to what was shown in the murine model, in this human study, we demonstrated that E. faecalis strains exploit the fibrinogen deposited on human catheters in a mechanism that involves recognition of fibrinogen by the EbpA tip adhesin of the Ebp pilus12. The N-terminus of EbpA contains conserved domains resembling blood clotting factors and a vWA domain containing a metal-ion dependent adhesion site (MIDAS)- implicated in fibrinogen binding12. Since vaccination with EbpA’s fibrinogen-binding domain provides protection against E. faecalis in the murine CAUTI model, the data from this study suggests that a similar vaccine may prove efficacious in human catheter-associated infections. This would be particularly valuable to prevent CAUTI by VRE and may help prevent sequela in the healthcare setting.

The observation that fibrinogen promoted colonization by other uropathogens, suggests that a similar strategy may also prove efficacious. For S. aureus, at least 20 adhesins that interact with fibrinogen have been identified to date21. Several of these have been shown to promote the adherence of S. aureus to catheters coated with fibrinogen in vitro and to bind to fibrinogen in vivo21. Among the fungi, Candida species are amongst the most common uropathogens22. Interesting, like E. faecalis, Candida albicans adheres only poorly to bladder mucosa, but the risk of a urinary tract infection increases in the presence of an indwelling urinary catheter10, 23. It has been shown that Candida albicans encodes a fibrinogen-binding protein, Mp58, which is expressed during candidiasis24, 25. Thus, the fact that fibrinogen-binding proteins are widely distributed among common uropathogens suggests that fibrinogen-binding may be a common theme in CAUTI pathogenesis. Fibrinogen-binding has not been fully explored in E. coli, the most common CAUTI pathogen. However, the genomes of E. coli UTI strains typically encode as many as 16 operons encoding chaperone-usher (CUP) pili, each of which likely recognizes a distinct host receptor with stereo-chemical specificity26, 27. Thus, determining whether fibrinogen, or some other inflammatory protein that is deposited on catheters, is amongst the repertoire of receptors recognized by E. coli CUP pili is a priority. Identification and evaluation of fibrinogen-binding proteins among common CAUTI pathogens will likely identify numerous attractive targets for development of therapeutics.

While the current study has provided an important insight into CAUTI pathogenesis, further work will be required to more generally translate these observations to human disease. For example, while several catheters were obtained from patients 1) with neurogenic bladder or incontinence and 2) undergoing other non-surgical procedures that do not involve urinary manipulation other than catheterization, a limitation of this study was that it primarily included patients undergoing a surgical urological procedure. Thus, the effect of catheterization on bladder inflammation and fibrinogen release should also be evaluated in non-surgical patients or patients undergoing or other surgical procedures. In addition, analysis of catheter-associated fibrinogen deposition in cohorts of CAUTI patients is needed to elucidate the full range of uropathogens associated with fibrinogen binding and their complement of potential fibrinogen-binding proteins. These studies will focus efforts on development of next-generation therapies for treatment of catheter-associated infections.

CONCLUSIONS

Fibrinogen deposits on human urinary catheters in a time-dependent manner, and this event creates a microenvironment for catheter colonization by E. faecalis, S. aureus and C. albicans. The results of this work will lead future investigations that may focus on interventions by blocking fibrinogen-binding by uropathogens.

Acknowledgments

Funding: This work was supported by the 1F32DK104516-01 grant to A.L.F.-M., and the R01-DK051406, R01-AI108749-01, and P50-DK0645400 grants to A.L.F-M, J.N.W, H.L.S.IV, J.S.P., M.G.C., and S.J.H. from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

ABBREVIATIONS AND ACRONYMS

UTI Urinary tract infection
CAUTI Catheter-associated urinary tract infection
VRE Vancomycin-resistant enterococci
MRSA Methicillin-resistant Staphylococcus aureus
Ebp Endocarditis- and biofilm-associated pilus
CUP chaperon-usher pili
CFU colony forming unit
RRP Radical retropubic prostatectomy
PCNL Percutaneous nephrolithotomy
TURBT Transurethral resection of bladder tumor
SPT Suprapubic tube
N/A not applicable
N/I urine culture positive but bacteria not identified
Neg urine culture negative
None no antibiotics given
U/A unknown antibiotic treatment
BID on prescription

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest: No author has any conflicts of interest to disclose

REFERENCES

1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183(Suppl 1):S1. [PubMed] [Google Scholar]

2. Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269. [PMC free article] [PubMed] [Google Scholar]

3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1. [PubMed] [Google Scholar]

4. Uckay I, Sax H, Gayet-Ageron A, et al. High proportion of healthcare-associated urinary tract infection in the absence of prior exposure to urinary catheter: a cross-sectional study. Antimicrob Resist Infect Control. 2013;2:5. [PMC free article] [PubMed] [Google Scholar]

5. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001;7:342. [PMC free article] [PubMed] [Google Scholar]

6. Willson M, Wilde M, Webb ML, et al. Nursing interventions to reduce the risk of catheter-associated urinary tract infection: part 2: staff education, monitoring, and care techniques. J Wound Ostomy Continence Nurs. 2009;36:137. [PubMed] [Google Scholar]

7. Melzer M, Welch C. Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infections. Postgrad Med J. 2013;89:329. [PMC free article] [PubMed] [Google Scholar]

8. Rizvi M, Khan F, Shukla I, et al. Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: necessity for exploring newer treatment options. J Lab Physicians. 2011;3:98. [PMC free article] [PubMed] [Google Scholar]

9. Bouchillon S, Hoban DJ, Badal R, et al. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol J. 2012;6:74. [PMC free article] [PubMed] [Google Scholar]

10. Jain M, Dogra V, Mishra B, et al. Candiduria in catheterized intensive care unit patients: emerging microbiological trends. Indian J Pathol Microbiol. 2011;54:552. [PubMed] [Google Scholar]

11. Conover MS, Flores-Mireles AL, Hibbing ME, et al. Establishment and Characterization of UTI and CAUTI in a Mouse Model. J Vis Exp. 2015:e52892. [PMC free article] [PubMed] [Google Scholar]

12. Flores-Mireles AL, Pinkner JS, Caparon MG, et al. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci Transl Med. 2014;6:254ra127. [PMC free article] [PubMed] [Google Scholar]

13. Nallapareddy SR, Murray BE. Role played by serum, a biological cue, in the adherence of Enterococcus faecalis to extracellular matrix proteins, collagen, fibrinogen, and fibronectin. J Infect Dis. 2008;197:1728. [PMC free article] [PubMed] [Google Scholar]

14. Nallapareddy SR, Singh KV, Sillanpaa J, et al. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest. 2006;116:2799. [PMC free article] [PubMed] [Google Scholar]

15. Montealegre MC, La Rosa SL, Roh JH, et al. The Enterococcus faecalis EbpA Pilus Protein: Attenuation of Expression, Biofilm Formation, and Adherence to Fibrinogen Start with the Rare Initiation Codon ATT. MBio. 2015;6:e00467. [PMC free article] [PubMed] [Google Scholar]

16. Nielsen HV, Guiton PS, Kline KA, et al. The metal ion-dependent adhesion site motif of the Enterococcus faecalis EbpA pilin mediates pilus function in catheter-associated urinary tract infection. MBio. 2012;3:e00177. [PMC free article] [PubMed] [Google Scholar]

17. Goble NM, Clarke T, Hammonds JC. Histological changes in the urinary bladder secondary to urethral catheterisation. Br J Urol. 1989;63:354. [PubMed] [Google Scholar]

18. Peychl L, Zalud R. [Changes in the urinary bladder caused by short-term permanent catheter insertion] Cas Lek Cesk. 2008;147:325. [PubMed] [Google Scholar]

19. Parsons CL. Pathogenesis of urinary tract infections. Bacterial adherence, bladder defense mechanisms. Urol Clin North Am. 1986;13:563. [PubMed] [Google Scholar]

20. De Ridder DJ, Everaert K, Fernandez LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol. 2005;48:991. [PubMed] [Google Scholar]

21. Cheng AG, Kim HK, Burts ML, et al. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 2009;23:3393. [PMC free article] [PubMed] [Google Scholar]

22. Fisher JF, Kavanagh K, Sobel JD, et al. Candida urinary tract infection: pathogenesis. Clin Infect Dis. 2011;52(Suppl 6):S437. [PubMed] [Google Scholar]

23. R Y, M PS, U AB, et al. Candiduria: prevalence and trends in antifungal susceptibility in a tertiary care hospital of mangalore. J Clin Diagn Res. 2013;7:2459. [PMC free article] [PubMed] [Google Scholar]

24. Casanova M, Lopez-Ribot JL, Monteagudo C, et al. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun. 1992;60:4221. [PMC free article] [PubMed] [Google Scholar]

25. Sepulveda P, Lopez-Ribot JL, Murgui A, et al. Candida albicans fibrinogen binding mannoprotein: expression in clinical strains and immunogenicity in patients with candidiasis. Int Microbiol. 1998;1:209. [PubMed] [Google Scholar]

26. Wurpel DJ, Beatson SA, Totsika M, et al. Chaperone-usher fimbriae of Escherichia coli. PLoS One. 2013;8:e52835. [PMC free article] [PubMed] [Google Scholar]

27. Greene SE, Pinkner JS, Chorell E, et al. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. MBio. 2014;5:e02038. [PMC free article] [PubMed] [Google Scholar]

Which intervention is most appropriate for the treatment of a patient with functional urinary incontinence?

The most typical treatment for functional incontinence involves improving the patient's functional status, modifying transient causes for the incontinence (e.g., fecal impaction), and reducing environmental barriers to toileting or providing sufficient toileting assistance to avoid incontinence episodes.

What is the first line treatment for urge incontinence?

If you've been diagnosed with urge incontinence, one of the first treatments you may be offered is bladder training. Bladder training may also be combined with pelvic floor muscle training if you have mixed urinary incontinence.
If additional urine is needed, clamp the tubing below the port for 10-15 minutes or until urine appears. Clean the sample port of the catheter with an alcohol swab. Attach the Luer-lock syringe to the sample port of the catheter and withdraw 10-30 mL of urine; remove the syringe and unclamp the tubing.

When caring for a patient with urinary retention the nurse would anticipate an order for?

Fundamentals Exam 2.